07:21 AM EDT, 08/26/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday a phase 3 trial evaluating the investigational drug orforglipron in adults with obesity or overweight and type 2 diabetes met its primary and secondary endpoints.

The trial showed the drug delivered "significant" weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks.

For its primary endpoint, a once-daily 36 milligram dose of orforglipron lowered weight by an average of 10.5%, or 22.9 pounds, compared to 2.2%, or 5.1 pounds, with a placebo.

The company said it now has the full clinical data package to start regulatory submissions worldwide for orforglipron this year.

Eli Lilly ( LLY ) shares were up nearly 2% in recent premarket activity.